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Abstract
Insulin analogues are increasingly considered as an alternative to human insulin in the therapy of diabetes mellitus.
Insulin analogues (IAs) are chemically different from human insulin and may have different pharmacokinetic or
pharmacodynamic properties. The significance of the modifications of the insulin molecule for the safety profile of
IAs must be considered. This review describes the regulatory procedure and the expectations for the scientific
content of European marketing authorization applications for innovative IAs submitted to the European Medicines
Agency. Particular consideration is given to a potential cancer hazard. Specific regulatory guidance on how to
address a possible carcinogenic or tumor promoting effect of innovative IAs in non-clinical studies is available.
After marketing authorization, the factual access of patients to the new product will be determined to great extent
by health technology assessment bodies, reimbursement decisions and the price. Whereas the marketing
authorization is a European decision, pricing and reimbursement are national or regional responsibilities. The
assessment of benefit and risk by the European Medicines Agency is expected to influence future decisions on
price and reimbursement on a national or regional level. Collaborations between regulatory agencies and health
technology assessment bodies have been initiated on European and national level to facilitate the use of the
European Medicines Agency’s benefit risk assessment as basis on which to build the subsequent health technology
assessment. The option for combined or joint scientific advice procedures with regulators and health technology
assessment bodies on European level or on a national level in several European Member States may help
applicants to optimize their development program and dossier preparation in regard of both European marketing
authorization application and reimbursement decisions.
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Introduction
Subcutaneous insulin remains the backbone for the treat-
ment of diabetes mellitus in Europe when oral antidiabetic
medicinal products are not effective or no longer suffi-
cient. Alternative application routes for insulin have been
attempted for a long time to avoid inconvenient subcuta-
neous injections. An inhalative formulation of human
insulin has been licensed in 2006 but failed economic suc-
cess, was suspected to increase lung cancers in smokers
and was finally withdrawn from the market [1]. At var-
iance with the human insulin formulation for inhalation,
several IAs have been successfully introduced on the
European market. In an IA, the human insulin molecule
has been altered to modify its pharmacokinetic and/or
pharmacodynamic properties. The development of new
IAs continues regardless of an ongoing discussion on the
safety of these products [2,3]. Most particularly a possible
carcinogenic effect of IAs has been considered and since
2001 special recommendations of the European Medicines
Agency are available on how to assess a possible carcino-
genic potential of a new IA during development [4].
General legal and regulatory requirements for innovative
medicinal products
For the demonstration of efficacy, generally two pivotal
studies are expected. The studies should be compliant to
the principles of good clinical practice, prospective, dou-
ble-blind, randomized and statistically powered not only
for efficacy but also for the detection of more frequently
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parator is most welcome, but a non-inferiority design to
an active comparator is sufficient. Whether to include a
placebo arm in form of a three arm study design or
whether possibly to apply for a European marketing
authorization based on super i o r i t yt oap l a c e b oa l o n e
needs careful consideration.
Whereas efficacy is defined exclusively clinically, for the
assessment of the safety profile both the clinical safety
data and the non-clinical studies on toxicology and safety
pharmacology are important. In indications with, like dia-
betes mellitus, several well established treatment options,
the safety profile of a medicinal product is paramount. In
this case, it may not be sufficient to demonstrate that the
beneficial effects of the new product outweigh its unfa-
vourable effects. If medicinal products with similar efficacy
are available, the safety profile of the new product should
not be inferior to an established treatment option. Since a
head to head comparison with an established treatment is
best for a comparative assessment of efficacy and safety it
is generally advisable to include a state of the art active
comparator in a European marketing authorization
application.
Economic considerations, the question of the price of a
new medicinal product or whether it will be reimbursed
by health care systems have no part in the marketing
authorization decision that will be based on efficacy, safety
and pharmaceutical quality alone. All stakeholders, how-
e v e r ,n e e dt ok e e pi nm i n dt h a tt h eu l t i m a t eg o a lo fa n y
development is the use of the new product by the patients.
This will be greatly influenced by economic factors, e.g.
reimbursement decisions. The head to head comparison
with a standard treatment licensed in Europe is highly
recommended both for the marketing authorization appli-
cation and for the subsequent assessment for pricing and
reimbursement decisions. It seems advisable that com-
parative data required by health technology assessment
bodies are generated as early as possible, e.g. within in the
trials performed to support of the European marketing
authorization application.
Health technology assessment bodies and decision
makers on reimbursement and pricing are organized
nationally or even regionally. For example, there are 7
different regional health technology assessment bodies in
Spain (Agencia de Evaluación de Tecnologías Sanitarias
de Andalucía; Instituto Aragonés de Ciencias de la Salud;
Agència d’Avaluació de Tecnologia i Recerca Mèdiques
de Catalunya; Axencia de Avaliación de Tecnoloxías
Sanitarias de Galicia; Agencia Laín Entralgo de Madrid,
Unidad de Evaluación de Tecnologías Sanitarias, Comu-
nidad de Madrid; Osasun Teknologien Ebaluazioko
Zerbitzua, País Vasco; Servicio de Evaluación del Servicio
Canario de Salud) in addition to the national Spanisch
agency Instituto de Salud Carlos III-ISCIII [5].
Marketing authorizations for a medicinal product in
Europe may be obtained through national procedures in
the various member states with the subsequent option
of mutual recognition procedures in other member
states, through the Decentralized European Procedure in
member states selected by the applicant or through the
European Centralized Procedure. A successful marketing
authorization application in the Centralized Procedure
will result in a marketing authorization by the European
Commission for all member states of the European
Union and the countries of the European Economic
Area Iceland and Norway. Since 2004, all innovative
medicinal products with the indication diabetes mellitus
and all biotechnology medicinal products are in the
mandatory scope of the Centralized Procedure. IAs,
therefore, need to use the Centralized Procedure.
The Centralized Procedure for Marketing
Authorization in Europe
For the Centralized Procedure, the marketing authoriza-
tion application is submitted to the European Medicines
Agency in London, which is in the centre of the European
network of Regulatory Agencies and based on the scienti-
fic expertise of about 4000 scientists at 44 regulatory agen-
cies all over Europe. The European Medicines Agency is
responsible for the selection of the assessment teams with
the best available expertise for the function of Rapporteur
and Corapporteur and for the procedural management.
The scientific assessment is performed by the Rapporteur’s
and Corapporteur’s multidisciplinary teams at the national
regulatory agencies in the member states of the European
Union. The final recommendation whether to grant a
marketing authorization is consolidated in the European
Medicines Agency’s scientific Committee for Medicinal
Products for Human Use.
The 27 member states of the European Union send
one delegate each to this committee. These elect five
co-opted members to provide additional expertise on
particularly relevant areas and each of the additional
members of the European Economic Area Iceland and
Norway send a delegate (Figure 1). In monthly meetings,
the committee members discuss the marketing authori-
zation application and try to reach a consensus position.
If no consensus is possible a recommendation based on
a majority of at least 17 votes from delegates from the
European Union member states or co-opted members
will be given to the European Commission.
Demonstration of Efficacy and Safety in a European
Marketing Application for innovative IAs
A European marketing authorization application for an
innovative IA must include the demonstration of clinical
efficacy and safety. Glycated haemoglobin (HbA1c) is an
accepted surrogate parameter for treatment efficacy
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will be very welcome. If HbA1c is used as an endpoint
in a superiority design, it should be made obvious that
the treatment-induced change, the difference in HbA1c
between the group using the new medicinal product and
the reference group is not only statistically significant
but also clinically relevant. If HbA1c is used as an end-
point in a non-inferiority design, the non-inferiority
margin needs to be justified to ensure that any differ-
ence in treatment effect within this margin is of no clin-
i c a lr e l e v a n c e[ 6 ] .T h i si si m p o r t a n ts i n c eag l u c o s e
control even slightly inferior compared to the estab-
lished treatment might result in less favourable outcome
over a long time. Any potential or observed inferior effi-
cacy should be set in relation to other possible advan-
tages of the innovative medicinal product, e.g. with
regard to safety such as lower risk of hypoglycaemia,
favourable effect on body weight or improvement of
patient compliance.
With several established treatment options available for
diabetes mellitus including various human insulin pre-
parations and IAs and the expectation of long term use
of a new IA, safety aspects are crucial. Amongst others,
data supporting the cardiovascular safety of the new anti-
hyperglycaemic agent are expected. Regulators are very
aware of the importance of this endpoint, especially since
the suspension of the marketing authorisations for the
rosiglitazone-containing anti-diabetes medicines [7].
These products exhibited a seemingly beneficial effect on
glucose control that did not translate into an improved
cardiovascular outcome but, to the contrary, data even
suggested cardiovascular harm. According to current
guidelines, clinical safety studies should cover a time per-
i o do fa tl e a s t6m o n t h s .I fapaediatric indication is
applied for, a time period of at least two years should be
used, looking for signals of immunogenicity or carcino-
genicity. With the imminent revision of the European
Medicines Agency’s guideline on medicinal products in
the treatment of diabetes mellitus it is expected that clin-
ical trials of at least 18 to 24 months will be requested
prior to granting a European marketing authorization. As
it is obvious that an 18 to 24-month follow-up is most
likely completely insufficient to detect a possible increase
in tumours the matter of carcinogenicity needs to be
thoroughly addressed in non-clinical studies.
Studies on the potential cancer hazard of IAs
After the discovery of the potent carcinogenic effect of
AspB10 in rats the European Medicines Agency issued a
detailed guidance on what should be done to exclude or
minimize the carcinogenic hazard for new IAs. In the
“Points to consider document on the non-clinical assess-
ment of the carcinogenic potential of insulin analogues”
[4]in vitro and in vivo studies are described that may be
appropriate to address the possible carcinogenicity of a
new IA. In this document, an IA-induced increase in cell
proliferation mediated by cross-reactivity with insulin-like
growth factor 1 (IGF-1) at the IGF1 receptor (IGF1R) was
considered the most likely mechanism. The statement: “...
insulins with an increased mitogenic effect in comparison
to the native human insulin in current use would consti-
tute a major public health concern“ makes clear that this
hazard of IAs is taken most seriously. From today’sp e r -
spective, almost ten years after adoption of the guidance
document, this position may seem over-cautious. It is
uncertain whether a new IA with such effects on cell pro-
liferation could today or in the future get a positive recom-
mendation for marketing authorization by the European
Medicines Agency’s Committee for Medicinal Products
for Human Use. For IAs already licensed, however, effects
on proliferation that have been seen in non-clinical experi-
ments in combination with ultimately inconclusive epide-
miological studies on the occurrence of cancer in humans
were not considered sufficient for a suspension or withdra-
wal of the European marketing authorization by the
European Medicines Agency. Insulin glargine has been
shown to act stronger than human insulin on cell prolif-
eration in selected breast cell lines, [8,9] in colon cancer
cell lines [10], and in human lung fibroblasts [11]in vitro.
Some epidemiological studies seemed to suggest an
Figure 1 Co-opted members: members who provide additional
expertise in a particular scientific area - i.e.: medical statistics;
pharmacovigilance, pharmacoepidemiology; quality (non-
biologicals), quality and safety (biological), with expertise in
advanced therapies (gene, cell and tissue therapies). Delegates:
CHMP members and alternates nominated by each of the EU-
member states in consultation with the EMA Management Board.
EEA: European Economic Area: Member States of the EU + 2
delegates from Iceland and Norway.
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[13] in patients treated with an IA, while other clinical stu-
dies failed to find an increase in cancer [14] or the authors
c o n c l u d e dt h a tt h eo b s e r v e di n c r e a s ei nb r e a s tc a n c e r
reflected allocation bias rather than an effect of insulin
g l a r g i n e[ 1 5 ] .T h eb e s tw a yt oo v e r c o m et h e s ei n h e r e n t
limitations of epidemiological studies would be a well
designed, prospective randomized controlled trial. How-
ever, the long time required to obtain meaningful result-
son the occurrence of cancer in such a trial and the ethical
problems of a “carcinogenicity” study in humans [16]
make this approach unfeasible. Therefore, any regulatory
decision will be based on a wholistic view integrating epi-
demiological observational data as well as preclinical stu-
dies on possible mechanisms. Overall, data on the effect of
insulin glargine on the development of tumours are mostly
considered as inconclusive and a change of treatment
recommendations or regulatory action seem not justified
to experts in the USA [17] or in Europe [2,18,19].
Whereas the interaction of IAs with the IGF1R is con-
sidered the predominant mechanism for the induction of
cancer, the European Medicines Agency’s “points to con-
sider document” [4] does not exclude other possible
mechanisms: “Although enhanced Insulin-like Growth
Factor 1 (IGF-1) receptor activation and/or aberrant sig-
nalling through the insulin receptor have been implicated,
the mechanism(s) responsible for the mitogenic activity
remain to be clarified.” The European Medicines Agency
rather emphasize the need for further mechanistic stu-
dies: “The exact mechanism(s) behind the increased carci-
nogenic and/or mitogenic potential of some insulin
analogues remain to be elucidated”. Consequently, the
non-clinical studies on carcinogenicity of IAs are not to
be restricted to IGF1R-mediated effects but “...interaction
with growth factor receptors and mechanisms other than
those for IGF-1 need to be taken into account.” To mini-
mize the hazard of a carcinogenic or tumour-promoting
effect of a new IA, comprehensive experimental investi-
gations of the effects of IAs on normal and malignant
cells are recommended. In addition to the standard pack-
age of pharmacology, toxicology and safety pharmacology
studies, recommendations for some special studies are
given for innovative IAs. The receptor binding profile of
a new IA should be thoroughly characterized. As the
minimum it is recommended to study the effects on insu-
lin receptor and IGF-1R. The ligands human insulin,
IGF-1, and AspB10 should be included as controls in all
experiments. The quantitative comparison of the mito-
genic versus the metabolic activity of an innovative IA is
important for the overall conclusion on its biological
effects. Always in comparison with human insulin, IGF-1,
and AspB10, the metabolic activity should be studied in
an assay that has been shown to be most sensitive for
effects on the carbohydrate metabolism. In parallel, the
mitogenic activity should be studied in an assay that has
been shown to be most sensitive for effects on cell prolif-
eration. Finally, the effects on carbohydrate metabolism
and cell proliferation should be assessed simultaneously
in cells that react to both the mitogenic and the meta-
bolic properties of the IA. It is acceptable, that such cells
may be less sensitive to either of the effects.
For a new IA the exact mechanism of carcinogenicity (if
any) may be unknown. The IGF1-R mediated increase in
cell proliferation may not be the only mechanism by
which IAs potentially induce or promote cancer. There-
fore, studies in cell culture may not be sufficient. Addi-
tional studies in tissues (ex vivo) may be integrated in the
standard toxicology studies e.g. in the repeated dose toxi-
city studies. The selection of strain and species is crucial
for the relevance of these studies for humans. It is recom-
mended to use a species or strain for which the mito-
genic/metabolic potency ratio is similar to man.
It has been recognized that normal and malignant cells
or tissues may react differently to IAs. Additional studies
with neoplastic tissues may be helpful and should be
g i v e nc o n s i d e r a t i o no nac a s eb yc a s eb a s i sa l t h o u g ht h i s
approach clearly exceeds the classical approach in toxico-
logical studies using healthy animals.
The interface between regulatory and health
technology assessment
The demonstration of efficacy, safety and pharmaceutical
quality may be sufficient to attain the European marketing
authorization. This may, however, not be equal to the fac-
tual access of patients to the new product as pricing and
reimbursement decisions depend on national or regional
health systems [20]. It has become increasingly difficult
within the European Union to explain divergent assess-
ments and decisions by health technology assessment
bodies and regulatory agencies. In the public perception, a
positive opinion of the regulators on an innovative new
product and the subsequent denial of reimbursement by
health technology assessment bodies are contradictory. To
minimize differences in the assessments of regulators and
health technology assessment bodies, the European net-
work for Health Technology Assessment (EUnetHTA)
and the European Medicines Agency started collaboration
on European Public Assessment Report contribution to
relative effectiveness assessment in February 2010 [21]. By
now, the contents and structure of regulators’ assessment
reports and most particularly the benefit risk section has
been modified to better suit the health technology assess-
ment bodies’ needs.
The new structure of European Public Assessment
Reports (Table 1) is meant to facilitate the use of the
assessment by health technology assessment bodies. In
the European Public Assessment Reports beneficial and
unfavourable effects will be quantitatively described and
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weight the beneficial and unfavourable effects, give their
relative importance and describe possible trade-offs.
The new standardized description will be an integral
part of the assessment report for any new application.
This will lead to the development of a system of clearly
assigned values and trade-offs which over time may
develop into a European database for weighted relative
benefits. This data base may be used by health technol-
ogy assessment bodies all over Europe for value-based
price finding providing a generally accepted understand-
ing on benefits and risks as a common basis to which
the specifics of the national or regional health care sys-
tem or economics are added. Therefore, applicants may
want to take this aspect - price and reimbursement -
into consideration when preparing their European mar-
keting authorization application.
To foster the early alignment of different stakeholders,
j o i n ts c i e n t i f i ca d v i c ep r o c e d u r e sb yr e g u l a t o r sa n d
health technology assessment bodies are developed on
European or national level [22-24]. This is a promising
way to avoid European marketing authorization deci-
sions that have little or no consequence for patients
who do not have access to the licensed product for eco-
nomic reasons.
This sort of exchange, collaboration and ultimately
alignment may be a clear win-win situation: patients and
their physicians would certainly welcome if clinical prac-
tice and international treatment guidelines and recom-
mendations were better in line with regulatory and
reimbursement decisions. Health technology assessment
bodies and payers could better benefit from the regula-
tors work and more easily build their own assessment on
top of the regulators’ assessment. To facilitate this, their
needs with regard to structure and contents of the regu-
lators assessment reports must be met. Industry should
be interested in a better predictability of regulators’ and
health technology assessment bodies’ decisions.
Whereas this alignment process may be relevant for
all innovative medicinal products, it may be particularly
relevant in the ongoing discussion on the price and
reimbursement for IAs in important European markets
[25].
Conclusions
For innovative IAs specific regulatory guidance for Eur-
opean marketing authorization application is available.
In addition to the basic demonstration of efficacy and
safety, particular consideration is given to a potential
cancer hazard. Additional studies exceeding the usual
safety package that may address this issue have been
suggested by the European Medicines Agency. Com-
bined or joint scientific advice procedures from regula-
tors and health technology assessment bodies are
developing on the European level and on a national
level in several European Member States.
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